Fibrocell Science (NASDAQ:FCSC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright set a $6.00 target price on shares of Fibrocell Science and gave the company a “buy” rating in a research note on Tuesday, January 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $3.94.
Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Monday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.07. analysts predict that Fibrocell Science will post -1.63 earnings per share for the current fiscal year.
In other Fibrocell Science news, major shareholder Randal J. Kirk bought 2,727,273 shares of Fibrocell Science stock in a transaction dated Monday, December 11th. The shares were bought at an average price of $0.77 per share, with a total value of $2,100,000.21. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC bought a new position in Fibrocell Science during the 3rd quarter worth approximately $909,000. Parametric Portfolio Associates LLC boosted its stake in Fibrocell Science by 264.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after acquiring an additional 35,000 shares during the last quarter. FNY Partners Fund LP bought a new position in Fibrocell Science during the 4th quarter worth approximately $129,000. Armistice Capital LLC bought a new position in Fibrocell Science during the 4th quarter worth approximately $393,000. Finally, Third Security LLC boosted its stake in Fibrocell Science by 49.2% during the 4th quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock worth $5,292,000 after acquiring an additional 2,727,273 shares during the last quarter. 43.00% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Fibrocell Science (FCSC) Rating Lowered to Hold at Zacks Investment Research” was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/fibrocell-science-fcsc-rating-lowered-to-hold-at-zacks-investment-research.html.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.